|
Date: May 16, 2012
| 
|
NEW YORK (Reuters Health) - A company-sponsored study of natalizumab has confirmed that the drug raises the risk of progressive multifocal leukoencephalopathy (PML), and that the risk can be as high as 1.11% when used for a long time in multiple sclerosis (MS) patients who have been exposed to immunosuppressant drugs and the John Cunningham (JC) virus, which causes PML.
Date: May 14, 2012
|
|
NEW YORK (Reuters Health) - People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping. And a new clinical trial suggests they are not just blowing smoke.
Date: May 14, 2012
|
|
WASHINGTON (Reuters) - U.S. health regulators said on Monday they could not definitively link Novartis AG's multiple sclerosis pill Gilenya (fingolimod) with the deaths of people who took the drug.
Date: May 10, 2012
|
|
WASHINGTON (Reuters) - U.S. drug regulators are warning people with multiple sclerosis (MS) to avoid an experimental treatment that props open internal veins in the neck and chest, because it can cause death or serious injury.
Date: May 7, 2012
|
|
HARTFORD, Conn. (Reuters) - The Connecticut Senate passed a bill on Saturday legalizing marijuana use for medical purposes with tight restrictions aimed at avoiding problems that have plagued some of the 16 other states where marijuana is now legal.
Date: Apr 25, 2012
|
|
Date: Apr 20, 2012
|
|
NEW YORK (Reuters Health) - Omega-3 fatty acid supplementation did not have beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis (MS) in the randomized, double-blind, placebo-controlled OFAMS study reported online April 16 in Archives of Neurology.
Date: Apr 20, 2012
|
|
LONDON (Reuters) - European and U.S. regulators have backed the continued use of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said on Friday the drug needed to carry stronger warnings on heart risks.
Date: Apr 13, 2012
|
|
ZURICH (Reuters) - A patient taking Novartis's multiple sclerosis pill Gilenya (fingolimod) developed a rare and often fatal viral disease, the Swiss drugmaker said on Friday, an unwelcome development as European authorities conclude a probe into the drug's safety.
|
| 
Practice Tools
